Interim Report January – September 2019
The day will start off with registration at 1:30 p.m. The program begins at 2:00 p.m. and will conclude with a “meet and greet” and light refreshments at 5:00 p.m. The event will take place in the IVA Conference Center’s Wallenberg Hall at Grev Turegatan 16 in Stockholm.
Registration applications can still be sent to firstname.lastname@example.org.
The written presentations will be in English but the lectures will mainly be held in Swedish.
Program: 2:00 – 5:00 p.m.
2:00 Welcome by Moderator Lars Frick and CEO Erik Kinnman
2:05 Magnus Persson – Associate Professor in physiology, private equity investor and Director of the Board – gives his view of why investments in pharmaceutical development within rare diseases are highly interesting
2:30 Dr Amel Karaa – Massachusetts General Hospital – international expert in primary mitochondrial diseases, describes the unmet medical need and the research development within the field
3:00 CEO Erik Kinnman presents NeuroVive’s updated strategy, the portfolio and describes the background
3:30 Coffee break: Take the opportunity to ask questions
4:00 CMO Magnus Hansson and CSO Eskil Elmér give a closer description of the company’s central projects and its external collaborations
4:30 Matilda Hugerth – Director Clinical & Regulatory Affairs – describes orphan drugs and their regulatory path to market
5:00 Conclusions followed by mingle and refreshments
The Capital Markets Day will be moderated by Lars Frick of the equities publication Börsveckan.
The program will be available on NeuroVive’s website after the event. There will also be a live webcast via https://tv.streamfabriken.com/neurovive-cmd-2019.